Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bachelez

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Annales De Dermatologie Et De Venereologie|May 16, 2009
[Biotherapies for psoriasis: Options following the suspension of Raptiva?]F Aubin, H Bachelez, J-C Beani, et al.
The British Journal of Dermatology|April 14, 2019
PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimensJ Gottlieb, M Madrange, C Gardair, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 26, 2014
Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and cliniciansH Gilet, A Roborel de Climens, B Arnould, et al.
Journal of Autoimmunity|March 14, 1998
Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4H Bachelez, B Flageul, L Dubertret, et al.
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2018
Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015L Polivka, N Oubaya, H Bachelez, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2020
Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre studyM-A Richard, C Paul, G De Pouvourville, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Predictors of long-term drug survival for infliximab in psoriasisQ Magis, D Jullien, C Gaudy-Marqueste, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2022
Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohortF Assan, B Husson, S Hegazy, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Annales De Dermatologie Et De Venereologie|May 16, 2009
[Biotherapies for psoriasis: Options following the suspension of Raptiva?]F Aubin, H Bachelez, J-C Beani, et al.
The British Journal of Dermatology|April 14, 2019
PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimensJ Gottlieb, M Madrange, C Gardair, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 26, 2014
Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and cliniciansH Gilet, A Roborel de Climens, B Arnould, et al.
Journal of Autoimmunity|March 14, 1998
Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4H Bachelez, B Flageul, L Dubertret, et al.
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2018
Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015L Polivka, N Oubaya, H Bachelez, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2020
Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre studyM-A Richard, C Paul, G De Pouvourville, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Predictors of long-term drug survival for infliximab in psoriasisQ Magis, D Jullien, C Gaudy-Marqueste, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2022
Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohortF Assan, B Husson, S Hegazy, et al.
Pageof 14